| 摘要 |
The present invention provides novel compounds represented by the general formula (I) wherein m is an integer of from 1 to 3; n is O or an integer of from 1 to 4; R is selected from the group consisting of CO2H, CO2R<6>, CH2OH, CH2OR<6> (II), and CONR<3>R<4>; R<1> and R<2> are independently selected from the group consisting of H, R<6>, C1-C6 alkenyl, C1-C6 alkynyl, C<3>-C<7> cycloalkyl, C4-C12 alkylcycloalkyl, C6-C10 aryl, C7-C12 alkyl aryl radicals and heteroatom-substituted derivatives thereof, wherein one or more of the hydrogen or carbon atoms in said radicals is replaced with a halogen, nitrogen or sulfur-containing radical; R<3> and R<4> are selected from the group consisting of H and R<6> , and X is selected from the group consisting of H, R<6>, hydroxy. N(R<6>)2, CON(R<6>)2, SR<6>, sulfoxy, sulfone, halogen, COOR<6>, NO2, CN and OR<6>, wherein R<6> is C1-C6 alkyl; Y is O or S; Z is N or CH and pharmaceutically acceptable salts thereof. The novel compounds are PGF2 alpha antagonists, useful in pharmaceutical compositions for treating PGF2 alpha -mediated disease responses such as inflammatory reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), excessive bone breakdown (osteoporosis), peptic ulcers, heart disease, platelet aggregation and thrombosis. |
